Prof. Annette G. Beck-Sickinger was awarded with the Max-Bergmann-Medal 2009 for her seminal work on the NPY receptor system on occasion of the annual meeting of the Max-Bergmann-Society in Gotha, Germany, October 4–7, 2009. The review covers the topic of the Award Lecture.
Neuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development
Article first published online: 24 FEB 2011
Copyright © 2011 European Peptide Society and John Wiley & Sons, Ltd.
Journal of Peptide Science
Volume 17, Issue 4, pages 233–246, April 2011
How to Cite
Walther, C., Mörl, K. and Beck-Sickinger, A. G. (2011), Neuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development. J. Peptide Sci., 17: 233–246. doi: 10.1002/psc.1357
- Issue published online: 9 MAR 2011
- Article first published online: 24 FEB 2011
- Manuscript Accepted: 7 JAN 2011
- Manuscript Revised: 22 DEC 2010
- Manuscript Received: 2 DEC 2010
- structure-activity relationship;
- drug development;
- receptor trafficking
NPY, PYY and PP constitute the so-called NPY hormone family, which exert its biological functions in humans through YRs (Y1, Y2, Y4 and Y5). Systematic modulation of YR function became important as this multireceptor/multiligand system is known to mediate various essential physiological key functions and is involved in a variety of major human diseases such as epilepsy, obesity and cancer. As several YRs have been found to be overexpressed on different types of malignant tumors they emerge as promising target in modern drug development. Here, we summarize the current understanding of YRs function and the molecular mechanisms of ligand binding and trafficking. We further address recent advances in YR-based drug design, the development of promising future drug candidates and novel approaches in YR-targeted tumor diagnostics and therapy opportunities. Copyright © 2011 European Peptide Society and John Wiley & Sons, Ltd.